Last updated: September 3, 2026
Macimorelin acetate, marketed as Macrilen, is an FDA-approved oral diagnostic for adult growth hormone deficiency. Its commercial opportunity is limited by a small diagnostic population, specialist prescribing, reimbursement friction, and competition from established stimulation tests. The product has a differentiated safety and convenience profile, but it has not developed into a large pharmaceutical franchise. Its financial trajectory remains in the low-single-digit-million-dollar range, with commercial control returning to Aeterna Zentaris after Novo Nordisk exited the North American arrangement.
What is macimorelin acetate and what is Macrilen used for?
Macimorelin acetate is an orally administered ghrelin receptor agonist used to stimulate growth hormone secretion during diagnostic testing for adult growth hormone deficiency.
The FDA approved Macrilen on December 20, 2017, for use in adults with suspected adult growth hormone deficiency. The approved diagnostic protocol uses a single oral dose of 0.5 mg/kg, followed by blood sampling for growth hormone concentrations at specified intervals.[1]
| Product attribute |
Detail |
| Active ingredient |
Macimorelin acetate |
| Brand |
Macrilen |
| Therapeutic role |
Diagnostic stimulation test |
| Disease area |
Adult growth hormone deficiency |
| FDA approval |
December 20, 2017 |
| Administration |
Oral solution prepared from powder |
| Sponsor at approval |
Aeterna Zentaris |
| Commercial partner |
Novo Nordisk in the United States and Canada |
| Primary alternatives |
Insulin tolerance test, glucagon stimulation test, arginine-based testing |
| Product type |
Small-molecule diagnostic drug |
Macimorelin is not a growth hormone replacement product. It does not treat growth hormone deficiency directly and does not compete with somatropin or long-acting growth hormone therapies on a prescription-value basis.
How large is the macimorelin acetate market?
The addressable market is narrow because macimorelin is used only for diagnostic confirmation of suspected adult growth hormone deficiency.
Adult growth hormone deficiency is most commonly evaluated in patients with pituitary disease, hypothalamic tumors, prior cranial irradiation, traumatic brain injury, or multiple pituitary hormone deficiencies. Diagnosis generally requires biochemical stimulation testing because a random growth hormone measurement is not reliable.[2]
Market demand is constrained by four factors:
- The patient population requiring formal stimulation testing is relatively small.
- Endocrinologists may use established testing protocols that are already embedded in hospital workflows.
- Reimbursement varies by payer and site of care.
- Growth hormone replacement is generally reserved for confirmed cases, limiting the number of diagnostic tests tied to treatment initiation.
Macimorelin’s commercial advantages are most relevant where the insulin tolerance test is unsuitable. The insulin tolerance test can cause hypoglycemia and requires close monitoring. Macimorelin is oral, does not intentionally induce hypoglycemia, and can be administered in outpatient settings.
Its principal commercial weakness is that many endocrinology centers have long-standing protocols for insulin, glucagon, or arginine stimulation. Switching tests requires staff education, payer acceptance, protocol revision, and confidence in diagnostic cutoffs.
What is the financial trajectory of Macrilen?
Macrilen has generated commercial revenue but has remained a small product relative to conventional pharmaceutical franchises. Aeterna Zentaris has historically reported revenue associated with Macrilen, licensing, product sales, and related arrangements in its corporate financial statements. The company’s annual revenue profile has generally remained in the low-single-digit millions rather than reaching the scale of a broad specialty pharmaceutical product.[3][4]
Financial trajectory by commercial phase
| Period |
Commercial development |
Financial implication |
| 2017-2018 |
FDA approval and initial launch preparation |
Significant regulatory and launch costs |
| 2018-2022 |
Novo Nordisk commercialized Macrilen in North America |
Distribution and field-commercial capabilities improved, but sales remained niche |
| 2022-2023 |
Continued specialty diagnostic commercialization |
Revenue remained modest and dependent on endocrinology adoption |
| 2023-2024 |
Aeterna reacquired North American commercial rights |
Aeterna regained product economics but also assumed greater commercialization responsibility |
| Forward outlook |
Focus on specialist adoption and geographic expansion |
Upside depends on penetration, reimbursement, and additional regulatory approvals |
Macrilen’s economics are shaped by product price, testing-center utilization, sales-force efficiency, and the cost of maintaining commercial infrastructure. A small diagnostic product can have attractive gross margins but still produce limited operating profit if the company must support regulatory, medical affairs, quality, distribution, and sales functions.
The reacquisition of rights from Novo Nordisk changed the financial profile. Under a licensing structure, Aeterna could receive royalties or other payments without carrying the full commercial cost base. Direct commercialization can increase gross revenue and strategic control but also increases selling, general and administrative expenses.
Which companies commercialize or compete with macimorelin?
Aeterna Zentaris is the principal company associated with Macrilen. Novo Nordisk previously held North American commercial rights under a licensing arrangement and later relinquished those rights, allowing Aeterna to resume control.[5]
Macimorelin competes primarily with diagnostic procedures rather than branded drugs.
Competitive diagnostic alternatives
| Diagnostic method |
Commercial advantage |
Main limitation |
| Macimorelin stimulation test |
Oral administration; avoids deliberate hypoglycemia |
Limited adoption and reimbursement experience |
| Insulin tolerance test |
Established reference method in many centers |
Hypoglycemia risk; intensive monitoring |
| Glucagon stimulation test |
Widely recognized alternative |
Longer testing process and variable diagnostic performance |
| Arginine-based testing |
Can be used where insulin is unsuitable |
Availability and local protocol differences |
| Arginine plus GHRH |
Strong historical diagnostic performance in some regions |
GHRH availability and geographic limitations |
Macimorelin’s competitive position is strongest in adult patients for whom insulin-induced hypoglycemia is contraindicated or impractical. It is weaker in institutions that already have high-throughput insulin or glucagon testing infrastructure.
What FDA regulatory status does Macrilen have?
Macrilen has FDA approval for diagnosing adult growth hormone deficiency. The FDA label identifies important limitations, including the need to interpret results within the context of the patient’s clinical condition and the potential for drug interactions affecting growth hormone secretion or metabolism.[1]
The product is a diagnostic drug rather than a therapeutic biologic. It therefore does not face biosimilar competition under the Biologics Price Competition and Innovation Act. Any future competing product would generally need to proceed through an applicable drug approval pathway, while generic competition could potentially arise through an abbreviated new drug application if the relevant exclusivity and patent barriers permit.
The product’s regulatory value comes from its approved diagnostic indication and clinical validation, not from a large body of treatment-related outcomes data.
When does macimorelin lose exclusivity?
Macimorelin’s exclusivity position depends on three separate factors: FDA statutory exclusivity, listed patents, and practical regulatory barriers.
FDA exclusivity
Macrilen received the standard period of new chemical entity exclusivity associated with approval of a new active ingredient. That period expired before the end of the 2020s. Any current competitive protection therefore depends more heavily on patent status, regulatory requirements, manufacturing capability, and market size.
Patent protection
The principal U.S. patent associated with macimorelin is U.S. Patent No. 9,340,614, covering macimorelin-related composition and pharmaceutical subject matter. The patent issued in 2016 and derives from an earlier priority filing, placing its base term in the late 2020s, subject to patent-term adjustment or other applicable changes.[6]
| Protection category |
Expected effect |
| New chemical entity exclusivity |
Expired |
| Composition and formulation patents |
Potential protection into the late 2020s |
| Method-of-use protection |
May restrict specific diagnostic uses if listed and enforceable |
| Trade secrets |
May protect manufacturing know-how but do not block an independently developed generic |
| Regulatory know-how |
Can slow competitive entry without creating formal exclusivity |
Exact Orange Book status can change through patent listing updates, delisting, expiration, litigation, or regulatory decisions. A generic applicant could challenge listed patents through a Paragraph IV certification before their expiration.
What patents protect Macrilen and its formulation?
The patent estate is narrower than the estates supporting chronic therapeutics or biologics. The key protection areas are:
- The macimorelin chemical entity and related salts.
- Pharmaceutical compositions containing macimorelin acetate.
- Oral dosage forms and reconstitution systems.
- Use of macimorelin to stimulate growth hormone secretion for diagnostic purposes.
- Manufacturing and formulation processes, where separately claimed.
The commercial product is supplied as a powder for oral solution. That dosage form creates potential formulation and manufacturing barriers, but it also gives generic developers a pathway to design around particular excipient, packaging, or reconstitution claims.
Formulation protection is commercially relevant because diagnostic products are used in controlled clinical workflows. A generic competitor would need to demonstrate pharmaceutical equivalence, stability, dose accuracy, and comparable administration performance. Those requirements are less demanding than the development burden for a biologic, but they still create execution costs in a very small market.
Are there Paragraph IV challenges to Macrilen?
Publicly visible patent litigation and Paragraph IV activity have not established a broad generic challenge comparable to those seen for major chronic therapies. The limited market size reduces the financial incentive for an ANDA applicant to incur development, certification, litigation, and launch costs.
A potential generic applicant would evaluate:
- The remaining term of listed patents.
- Whether the product requires a complex oral solution or kit-specific demonstration.
- The commercial price available to support a small-volume launch.
- Whether endocrinologists would switch from established diagnostic procedures.
- The risk of damages or an injunction if a Paragraph IV challenge fails.
The most likely generic entry scenario is a narrow, late-life challenge focused on price-sensitive health systems or specialty distributors. A first generic could obtain 180 days of generic exclusivity if it is the first successful Paragraph IV filer, but the value of that period would depend on the limited market size.
What litigation and settlement risks affect macimorelin?
Macimorelin has not generated a major public patent-litigation record comparable to blockbuster drugs. The commercial risk is therefore less concentrated in litigation and more dependent on market access, execution, and product adoption.
Potential disputes could involve:
- ANDA Paragraph IV patent challenges.
- Patent-term calculations.
- Orange Book listing disputes.
- Manufacturing or supply agreements.
- Licensing-rights interpretation following the Novo Nordisk transition.
- Product liability or diagnostic-performance claims.
- Reimbursement and coding disputes.
A settlement with a generic entrant could include a delayed-entry date, a license to launch before patent expiration, or restrictions on formulation and manufacturing claims. Because the market is small, a commercial settlement may be preferable to prolonged litigation if the challenger can demonstrate a credible launch plan.
How strong is the macimorelin patent estate?
The patent estate is moderate for a small-molecule diagnostic but not strong by specialty-pharmaceutical standards.
Strengths
- Macimorelin has an approved diagnostic use.
- The product’s oral formulation creates some product-specific development work.
- The main patent term extends into the late 2020s.
- Limited market size may discourage early generic litigation.
Weaknesses
- The active ingredient is a small molecule.
- New chemical entity exclusivity has expired.
- Generic developers can potentially design around narrow formulation or method claims.
- The product does not have the manufacturing complexity of a biologic.
- The diagnostic market may support only a limited premium over existing tests.
The estate’s practical value depends less on broad blocking power than on the timing of generic entry. A late-decade loss of core patent protection could expose Macrilen to rapid price erosion if a generic developer concludes that testing-center adoption is sufficient to support commercial launch.
What licensing deals affect Macrilen?
Aeterna Zentaris entered into a commercial relationship with Novo Nordisk for Macrilen in North America. Novo Nordisk brought greater commercial scale, endocrine-market access, and distribution capabilities. Aeterna retained the underlying product and development economics under the agreement.
Aeterna later announced the reacquisition of U.S. and Canadian rights from Novo Nordisk. The transaction returned commercial control to Aeterna but removed the benefit of a global endocrine-focused partner.[5]
Commercial impact of the licensing transition
| Issue |
Novo Nordisk period |
Aeterna-controlled period |
| Commercial reach |
Access to a large endocrine sales organization |
Smaller specialist commercial platform |
| Operating burden |
Shared through licensing structure |
More direct responsibility for promotion and distribution |
| Revenue quality |
Royalties or partner-related economics |
Greater potential for direct product revenue |
| Strategic control |
Shared with licensee |
Greater control over pricing and positioning |
| Execution risk |
Partner prioritization risk |
Limited commercial scale and resources |
The key financial question is whether direct ownership can increase net revenue faster than it increases commercial expenses.
What generic launch scenarios exist for Macrilen?
Three entry scenarios are commercially plausible.
Scenario 1: No meaningful generic before patent expiry
This outcome would occur if the market remains too small to justify an ANDA program or if formulation and patent risks remain unattractive. Aeterna could preserve pricing and focus on expanding testing-center adoption.
Scenario 2: First generic launch near patent expiry
A generic developer could file a Paragraph IV certification and negotiate a launch date near the expiration of the principal patent. This would create a short period of continued branded sales followed by rapid price competition.
Scenario 3: Multiple generic launches after core patent expiry
If more than one applicant enters, Macrilen could experience standard small-molecule erosion, including discounts to laboratories, hospitals, specialty pharmacies, and distributors. The magnitude would depend on whether physicians view Macrilen as clinically interchangeable with the branded product.
The most material launch risk is not biosimilar substitution. Macimorelin is a small molecule, so the relevant risk is generic substitution through the ANDA pathway.
How does macimorelin compare with growth hormone replacement products?
Macimorelin and growth hormone replacement products occupy separate positions in the treatment pathway.
| Factor |
Macimorelin |
Somatropin and long-acting growth hormone |
| Role |
Diagnostic |
Treatment |
| Treatment duration |
Single diagnostic episode |
Chronic or long-term |
| Revenue per patient |
Low |
Much higher |
| Market size |
Narrow |
Larger endocrine market |
| Regulatory class |
Small-molecule diagnostic drug |
Biologic |
| Competitive threat |
Diagnostic procedures and generics |
Biosimilars and competing biologics |
| Reimbursement focus |
Test coverage |
Chronic therapy coverage and prior authorization |
Macimorelin’s revenue opportunity per patient is limited, but successful diagnosis can support downstream growth hormone treatment. That indirect relationship may help adoption among endocrinologists, although the diagnostic product does not automatically capture value from subsequent therapy.
What revenue exposure does macimorelin create for Aeterna Zentaris?
Macrilen is strategically important to Aeterna because the company has a relatively limited commercial portfolio. The product can provide recurring revenue from diagnostic testing, but it also creates concentration risk.
Aeterna’s exposure includes:
- Dependence on one primary commercial product.
- Sensitivity to endocrinology referral volumes.
- Reimbursement and payer policy changes.
- Distributor inventory and ordering patterns.
- Manufacturing and supply continuity.
- Patent expiry in the late 2020s.
- The cost of maintaining a commercial organization for a niche product.
The product’s upside is tied to broader adoption of oral testing as an alternative to insulin tolerance testing. The downside is a slow adoption curve combined with limited ability to spread fixed commercial costs across a larger portfolio.
What is the outlook for macimorelin acetate?
Macimorelin’s financial outlook is best characterized as a niche, defensible diagnostic franchise rather than a high-growth pharmaceutical asset.
Near-term growth depends on:
- Converting additional endocrinology centers.
- Increasing use in patients unsuitable for insulin tolerance testing.
- Improving payer coverage.
- Expanding outside the United States where regulatory approval permits.
- Maintaining manufacturing reliability.
- Using clinical education to establish Macrilen in diagnostic protocols.
Longer-term value is constrained by patent expiry, the absence of chronic-use revenue, and the potential for generic substitution. Aeterna can improve economics through direct commercialization, but the company must demonstrate that incremental gross profit exceeds the costs of sales, medical education, distribution, and regulatory maintenance.
Key Takeaways
- Macimorelin acetate is an oral diagnostic for adult growth hormone deficiency, not a growth hormone treatment.
- Macrilen received FDA approval in December 2017.
- The market is small and specialist-driven, with demand concentrated in endocrinology testing centers.
- The principal competitors are insulin tolerance, glucagon, and arginine-based stimulation tests.
- Novo Nordisk previously commercialized Macrilen in North America; Aeterna Zentaris later reacquired those rights.
- Aeterna’s reported revenue trajectory has remained in the low-single-digit millions, consistent with a niche product.
- New chemical entity exclusivity has expired, leaving patent term and commercial barriers as the main defenses.
- The principal U.S. patent associated with macimorelin is U.S. Patent No. 9,340,614, with base protection extending into the late 2020s.
- Macrilen faces generic rather than biosimilar risk.
- The principal financial risk is product concentration combined with a narrow diagnostic market.
- The principal commercial opportunity is replacing or supplementing invasive stimulation tests in adult patients with suspected growth hormone deficiency.
FAQs
Is macimorelin acetate a growth hormone drug?
No. Macimorelin acetate stimulates endogenous growth hormone release for diagnostic testing. It does not replace growth hormone and is not a treatment for growth hormone deficiency.
Can Macrilen be used in children?
The FDA approval is for adults with suspected growth hormone deficiency. Pediatric use is not the approved indication.
Does Macrilen compete with somatropin?
No. Macrilen is a diagnostic test, while somatropin is a growth hormone replacement therapy. They are used at different stages of patient management.
What is the main clinical advantage of Macrilen?
Macrilen is administered orally and does not require deliberate induction of hypoglycemia, unlike the insulin tolerance test. This can make it useful when insulin-based testing is medically unsuitable.
What is the largest commercial risk for Macrilen?
The largest risk is limited market scale. Even with patent protection, the product must generate sufficient testing volume to support commercialization, medical education, distribution, and regulatory costs.
References
-
U.S. Food and Drug Administration. (2017). Macrilen (macimorelin) prescribing information. FDA.
-
Endocrine Society. (2011). Evaluation and treatment of adult growth hormone deficiency. The Journal of Clinical Endocrinology & Metabolism, 96(6), 1587-1609.
-
Aeterna Zentaris Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
-
Aeterna Zentaris Inc. (2022). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
-
Aeterna Zentaris Inc. (2023). Aeterna Zentaris reacquires North American rights to Macrilen from Novo Nordisk. Corporate press release.
-
U.S. Patent and Trademark Office. (2016). U.S. Patent No. 9,340,614, macimorelin-related pharmaceutical compositions and uses. United States Patent and Trademark Office.
